Guggenheim Capital LLC Acadia Pharmaceuticals Inc Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 55,811 shares of ACAD stock, worth $1.03 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
55,811
Previous 56,917
1.94%
Holding current value
$1.03 Million
Previous $924,000
7.14%
% of portfolio
0.01%
Previous 0.01%
Shares
27 transactions
Others Institutions Holding ACAD
# of Institutions
283Shares Held
158MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$788 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$254 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$252 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$222 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$110 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.97B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...